Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan®) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients
- 17 March 2009
- journal article
- research article
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 266 (12) , 1937-1944
Abstract
Photodynamic therapy (PDT) is a relatively new method of treating superficial tumours of the skin and mucosa. After the injection of a photosensitising agent, the tumour area is exposed to non-thermal laser light. This causes a phototoxic reaction, producing oxygen radicals that destroy tumour cells. From November 2003 to July 2007, a total of 35 patients with recurrent squamous cell carcinoma or secondary tumours of the head and neck region were treated with PDT at the German Armed Forces Hospital in Ulm. These patients had failed or found unsuitable for other treatments. Meta-tetrahydroxyphenylchlorin (mTHPC), known under the trade name of Foscan®, was used as the photosensitising agent. Local control was achieved in 21 patients (60%) and partial remission in 10 patients (28.5%). Four patients (11.5%) did not respond to PDT treatment. The mean duration of overall survival was 401.45 (±321.2) days, median was 356 after the completion of treatment. The mean duration of recurrence-free survival was 327.7 (±131.1) days, median was 181 for patients with complete remission. None of the patient developed serious complications. Photodynamic therapy is an important treatment option for patients who present with recurrent carcinoma or secondary tumours of the upper aerodigestive tract and who have failed or unsuitable for other treatments. Due to the excellent treatment results that have been achieved so far, PDT may in the future also play a role in the primary treatment of superficial tumours of the oral cavity, pharynx and larynx.Keywords
This publication has 29 references indexed in Scilit:
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy, or Chemotherapy Alone?Journal of Clinical Oncology, 2006
- Eine Kosten-Effektivitäts-Analyse der photodynamischen Therapie mit Foscan® (Foscan®-PDT) im Vergleich zu einer palliativen Chemotherapie bei Patienten mit fortgeschrittenen Kopf-Halstumoren in DeutschlandLaryngo-Rhino-Otologie, 2005
- mTHPC‐mediated photodynamic therapy for early oral squamous cell carcinomaInternational Journal of Cancer, 2004
- The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UKOral Oncology, 2004
- mTHPC‐mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patientsHead & Neck, 2004
- Clinical pharmacokinetic studies of tetra(meta‐hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengthsInternational Journal of Cancer, 1995
- Photodynamic therapy and the treatment of neoplastic diseases of the larynxThe Laryngoscope, 1994
- Photodynamic therapy of malignant and premalignant lesions in patients with ’field cancerization‘ of the oral cavityThe Journal of Laryngology & Otology, 1993
- Growth rate of head and neck tumorsEuropean Journal of Cancer and Clinical Oncology, 1982